Cognitive health begins at conception: addressing dementia as a lifelong and preventable condition

BMC Medicine

Andrew D Blackwell²  Vladimir Hachinski¹  Jennifer H Barnett² 

[1] Department of Clinical Neurological Sciences, London Health Sciences Centre, University of Western Ontario, University Hospital, 339 Windermere Road, London, Ontario, N6A 5A5, Canada;Cambridge Cognition Ltd, Tunbridge Court, Tunbridge Lane, Bottisham, CB25 9TU, UK

关键词: Epidemiology;    Prevention;    Alzheimer’s disease;    Dementia;   

Others  :  855364
DOI  :  10.1186/1741-7015-11-246

 received in 2013-08-16, accepted in 2013-10-22,  发布年份 2013

【 摘 要 】

Background

Dementia is a major public health problem that poses an increasing burden on the health and wealth of societies worldwide. Because the efficacy of current treatments is limited, increasing efforts are required to prevent the diseases that cause dementia.

Discussion

We consider the evidence that lifelong prevention strategies may be an effective way to tackle the national burden of dementia in the absence of a cure. The links between lifestyle and cardiovascular disease are widely understood and accepted, but health professionals and patients remain unconvinced about the extent to which risk for dementia can be modified. However, there is strong evidence that at least half of risk for dementia is attributable to lifestyle factors such as diet, exercise and smoking. Moreover, the disease processes that result in dementia develop over several decades, implying that attempts to ameliorate them need to start early in life. Some modifiable risk factors for dementia act from the earliest stages of life, including in utero.

Summary

Rebalancing efforts from the development of treatments to increased emphasis on prevention may be an alternative means to reducing the impact of dementia on society.

【 授权许可】

   
2013 Barnett et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Wimo A, Prince M: World Alzheimer Report 2010: The Global Economic Impact of Dementia. Alzheimer’s Disease International: London, UK; 2010.
• [2]National Collaborating Centre for Mental Health: Dementia: a NICE-SCIE Guideline on Supporting People with Dementia and Their Carers in Health and Social Care. London, UK: The British Psychological Society; 2007.
• [3]Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997, 277:813-817.
• [4]Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) Lancet 2001, 357:169-175.
• [5]Schneider JA, Arvanitakis Z, Bang W, Bennett DA: Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69:2197-2204.
• [6]Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, Griffith EY, Guzman VA, Meier IB, Zimmerman ME, Brickman AM: White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol 2013, 70:455-461.
• [7]Marchant NL, Reed BR, Sanossian N, Madison CM, Kriger S, Dhada R, Mack WJ, Decarli C, Weiner MW, Mungas DM, Chui HC, Jagust WJ: The aging brain and cognition: contribution of vascular injury and Aβ to mild cognitive dysfunction. JAMA Neurol 2013, 70:488-495.
• [8]Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ: Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain 2013, 136:2697-2706.
• [9]Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR, Weiner M, Shinto L, Aisen PS: Docosahexaenoic acid supplementation and cognitive decline in alzheimer disease: a randomized trial. JAMA 2010, 304:1903-1911.
• [10]Schor NF: What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 2011, 69:237-239.
• [11]Miller G: Pharmacology. The puzzling rise and fall of a dark-horse Alzheimer’s drug. Science 2010, 327:1309.
• [12]Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A: Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the Elderly Research Group. Neurology 2000, 54:S4-S9.
• [13]Bertram L, Tanzi RE: Thirty years of Alzheimer’s disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008, 9:768-778.
• [14]Yin Y-W, Li J-C, Wang J-Z, Li B-H, Pi Y, Yang Q-W, Fang C-Q, Gao C-Y, Zhang L-L: Association between apolipoprotein E gene polymorphism and the risk of vascular dementia: a meta-analysis. Neurosci Lett 2012, 514:6-11.
• [15]Rockwood K, Ebly E, Hachinski V, Hogan D: Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Arch Neuro 1997, 54:33-39.
• [16]Barnes DE, Yaffe K: The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol 2011, 10:819-828.
• [17]Xu WL, Atti AR, Gatz M, Pedersen NL, Johansson B, Fratiglioni L: Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 2011, 76:1568-1574.
• [18]Tolppanen A-M, Solomon A, Soininen H, Kivipelto M: Midlife vascular risk factors and Alzheimer’s disease: evidence from epidemiological studies. J Alzheimers Dis 2012, 32:531-540.
• [19]Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, Helkala E-L, Tuomilehto J, Soininen H, Nissinen A: Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005, 62:1556-1560.
• [20]Qiu C: Preventing Alzheimer’s disease by targeting vascular risk factors: hope and gap. J Alzheimers Dis 2012, 32:721-731.
• [21]Sofi F, Abbate R, Gensini GF, Casini A: Accruing evidence about benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010, 92:1189-1196.
• [22]Hamer M, Chida Y: Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med 2009, 39:3-11.
• [23]Orozco LJ, Buchleitner AM, Gimenez-Perez G, Roqué I, Figuls M, Richter B, Mauricio D: Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev 2008, 3:CD003054.
• [24]Sofi F, Capalbo A, Cesari F, Abbate R, Gensini GF: Physical activity during leisure time and primary prevention of coronary heart disease: an updated meta-analysis of cohort studies. Eur J Cardiovasc Prev Rehabil 2008, 15:247-257.
• [25]Peila R, White LR, Petrovich H, Masaki K, Ross GW, Havlik RJ, Launer LJ: Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study. Stroke 2001, 32:2882-2889.
• [26]Rodrigue KM, Rieck JR, Kennedy KM, Devous MD Sr, Diaz-Arrastia R, Park DC: Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol 2013, 70:600-606.
• [27]Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003, 163:1069-1075.
• [28]Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ: Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826.
• [29]Isaac MG, Quinn R, Tabet N: Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev 2008, 3:CD002854.
• [30]Malouf R, Grimley Evans J: Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev 2008, 4:CD004514.
• [31]de Boo HA, Harding JE: The developmental origins of adult disease (Barker) hypothesis. Aust NZ J Obstet Gynecol 2006, 46:4-14.
• [32]Brion M-JA, Lawlor DA, Matijasevich A, Horta B, Anselmi L, Araújo CL, Menezes AMB, Victora CG, Davey Smith G: What are the causal effects of breastfeeding on IQ, obesity and blood pressure? Evidence from comparing high-income with middle-income cohorts. Int J Epidemiol 2011, 40:670-680.
• [33]Isaacs EB, Gadian DG, Sabatini S, Chong WK, Quinn BT, Fischl BR, Lucas A: The effect of early human diet on caudate volumes and IQ. Pediatr Res 2008, 63:308-314.
• [34]Strauss RS: Adult functional outcome of those born small for gestational age: twenty-six-year follow-up of the 1970 British Birth Cohort. JAMA 2000, 283:625-632.
• [35]Huang TL, Carlson MC, Fitzpatrick AL, Kuller LH, Fried LP, Zandi PP: Knee height and arm span: a reflection of early life environment and risk of dementia. Neurology 2008, 70:1818-1826.
• [36]Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing X, Peck A: Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neuro 1988, 23:138-144.
• [37]Power C, Atherton K, Thomas C: Maternal smoking in pregnancy, adult adiposity and other risk factors for cardiovascular disease. Atherosclerosis 2010, 211:643-648.
• [38]Anstey KJ, Cherbuin N, Budge M, Young J: Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev 2011, 12:e426-e437.
• [39]Gustafson D: A life course of adiposity and dementia. Eur J Pharmacol 2008, 585:163-175.
• [40]Moffitt TE, Arseneault L, Belsky D, Dickson N, Hancox RJ, Harrington H, Houts R, Poulton R, Roberts BW, Ross S, Sears MR, Thomson WM, Caspi A: A gradient of childhood self-control predicts health, wealth, and public safety. Proc Natl Acad Sci U S A 2011, 108:2693-2698.
• [41]Valenzuela MJ, Sachdev P: Brain reserve and dementia: a systematic review. Psychol Med 2006, 36:441-454.
• [42]Sharpbrains: Web-based, Mobile and Biometrics-Based Technology to Assess, Monitor and Enhance Cognition and Brain Function. [http://sharpbrains.com/market-report/ webcite]
• [43]Ahmad S, Orrell M, Iliffe S, Gracie A: GPs’ attitudes, awareness, and practice regarding early diagnosis of dementia. Br J Gen Pract 2010, 60:e360-365.
• [44]Richard E, Andrieu S, Solomon A, Mangialasche F, Ahtiluoto S, van Charante EPM, Coley N, Fratiglioni L, Neely AS, Vellas B, van Gool WA, Kivipelto M: Methodological challenges in designing dementia prevention trials - The European Dementia Prevention Initiative (EDPI). J Neurol Sci 2012, 322:64-70.